Recap: ChemoCentryx Q3 Earnings
Shares of ChemoCentryx (NASDAQ:CCXI) fell 8.59% in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were down 59.09% year over year to ($0.35), which missed the estimate of ($0.31).
Revenue of $5,085,000 declined by 51.94% from the same period last year, which missed the estimate of $10,700,000.
Guidance
ChemoCentryx hasn't issued any earnings guidance for the time being.
ChemoCentryx hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Nov 09, 2020
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/ehp3weoi
Price Action
Company's 52-week high was at $65.43
Company's 52-week low was at $7.88
Price action over last quarter: Up 8.05%
Company Description
ChemoCentryx Inc is a biopharmaceutical company involved in discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
